![]() | |
Clinical data | |
---|---|
Other names | AZD9833 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H28F4N6 |
Molar mass | 476.524 g·mol−1 |
3D model (JSmol) | |
| |
|
Camizestrant is an investigational new drug that is being evaluated to treat breast cancer. [1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD). [2]